THU0425 Secukinumab Improves Signs and Symptoms of Active Psoriatic Arthritis in a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using a Subcutaneous Dosing Regimen (Future 2)

I.B. McInnes; P. Mease; B. Kirkham; A. Kavanaugh; C. Ritchlin; P. Rahman; D. van der Heijde; R. Landewé; P.G. Conaghan; A.B. Gottlieb; H. Richards; G. Ligozio; L. Pricop; S. Mpofu

doi:10.1136/annrheumdis-2015-eular.2265

THU0425 Secukinumab Improves Signs and Symptoms of Active Psoriatic Arthritis in a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using a Subcutaneous Dosing Regimen (Future 2)

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.2265 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 352.3-353 ◽

Cited By ~ 1

Author(s):

I.B. McInnes ◽

P. Mease ◽

B. Kirkham ◽

A. Kavanaugh ◽

C. Ritchlin ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Signs And Symptoms ◽

Controlled Study ◽

Dosing Regimen ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Future 2

Download Full-text

SAT0271 Continued Improvement of Signs and Symptoms in Ustekinumab-Treated Patients with Active Psoriatic Arthritis: Week 52 Results of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-eular.1996 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A674.2-A675

Author(s):

A. Kavanaugh ◽

I. B. McInnes ◽

A. B. Gottlieb ◽

L. Puig ◽

P. Rahman ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Signs And Symptoms ◽

Controlled Study ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

THU0411 Secukinumab Efficacy in Anti-TNF-Naive and Anti-TNF-IR Patients with Psoriatic Arthritis: Results of a Phase 3 Multicenter, Double-Blind, Placebo-Controlled Study (Future 2)

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.2178 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 345.3-346 ◽

Cited By ~ 1

Author(s):

A. Kavanaugh ◽

I.B. McInnes ◽

S. Hall ◽

H. Chinoy ◽

A. Kivitz ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Study ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Future 2

Download Full-text

THU0421 Secukinumab is Effective in Reducing Dactylitis and Enthesitis Using Multiple Measures in Patients with Psoriatic Arthritis: Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (Future 2)

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.2276 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 351.1-351 ◽

Cited By ~ 8

Author(s):

B. Kirkham ◽

I.B. McInnes ◽

P. Mease ◽

J. Kremer ◽

S. Kandala ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Study ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Multiple Measures ◽

Future 2

Download Full-text

LB0001 Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24 week results of a phase 3 double blind randomized placebo-controlled study (rapid-PSA)

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.1961 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 150.3-151 ◽

Cited By ~ 6

Author(s):

P.J. Mease ◽

R. Fleischmann ◽

A. Deodhar ◽

J. Wollenhaupt ◽

D. Kielar ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Certolizumab Pegol ◽

Signs And Symptoms ◽

Controlled Study ◽

Phase 3 ◽

Double Blind

Download Full-text

228. Secukinumab, A Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicentre, Double-Blind, Placebo-Controlled Study

Rheumatology ◽

10.1093/rheumatology/kev089.115 ◽

2015 ◽

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Radiographic Progression ◽

Safety Data ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 17A

Download Full-text

THU0414 Secukinumab Inhibits Radiographic Progression in Patients with Psoriatic Arthritis: Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (Future 1)

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.1806 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 347.2-348 ◽

Cited By ~ 2

Author(s):

D. van der Heijde ◽

R. Landewé ◽

P. Mease ◽

I.B. McInnes ◽

P.G. Conaghan ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Radiographic Progression ◽

Controlled Study ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

OP0174 Efficacy and Safety of Ustekinumab in Psoriatic Arthritis Patients with Spondylitis and Peripheral Joint Involvement: Results from a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.3096 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 136.1-136 ◽

Cited By ~ 3

Author(s):

A. Kavanaugh ◽

L. Puig ◽

A.B. Gottlieb ◽

C. Ritchlin ◽

Y. You ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Study ◽

Joint Involvement ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Long‐term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through 2 Years: Results from a Phase 3, Randomized, Double‐blind, Placebo‐controlled Study Conducted in Biologic‐naïve Patients with Active Psoriatic Arthritis

Arthritis & Rheumatology ◽

10.1002/art.42010 ◽

2021 ◽

Author(s):

Iain B. McInnes ◽

Proton Rahman ◽

Alice B. Gottlieb ◽

Elizabeth C. Hsia ◽

Alexa P. Kollmeier ◽

...

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Term Efficacy ◽

Interleukin 23

Download Full-text

Faculty Opinions recommendation of Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718074595.793524441 ◽

2016 ◽

Author(s):

Dafna Gladman

Keyword(s):

Psoriatic Arthritis ◽

Certolizumab Pegol ◽

Signs And Symptoms ◽

Controlled Study ◽

Phase 3 ◽

Double Blind

Download Full-text

Faculty Opinions recommendation of Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718074595.793488587 ◽

2013 ◽

Author(s):

Kamran Ghoreschi

Keyword(s):

Psoriatic Arthritis ◽

Certolizumab Pegol ◽

Signs And Symptoms ◽

Controlled Study ◽

Phase 3 ◽

Double Blind

Download Full-text